Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

General Counsel

See Remarks

Chief Financial Officer

Chief Executive Officer

Chief Scientific Officer

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-05-03	Premium	sold	Premium	Premium	Premium	-
2024-05-02	Premium	sold	Premium	Premium	Premium	-
2024-05-01	Premium	sold	Premium	Premium	Premium	-
2024-02-20	Premium	sold	Premium	Premium	Premium	-
2024-02-07	Premium	sold	Premium	Premium	Premium	General Counsel
2024-02-07	Premium	sold	Premium	Premium	Premium	See Remarks
2024-02-07	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-02-07	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-02-06	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-02-06	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-02-06	Premium	sold	Premium	Premium	Premium	See Remarks
2024-02-06	Premium	sold	Premium	Premium	Premium	General Counsel
2024-02-01	Premium	acquired	Premium	Premium	Premium	General Counsel
2024-02-01	Premium	acquired	Premium	Premium	Premium	See Remarks
2024-02-01	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-02-01	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2023-11-01	Premium	sold	Premium	Premium	Premium	See Remarks
2023-10-16	Premium	bought	Premium	Premium	Premium	-
2023-10-13	Premium	bought	Premium	Premium	Premium	-
2023-10-09	Premium	sold	Premium	Premium	Premium	-
2023-10-09	Premium	sold	Premium	Premium	Premium	-
2023-08-29	Premium	acquired	Premium	Premium	Premium	-
2023-08-11	Premium	acquired	Premium	Premium	Premium	-
2023-08-11	Premium	bought	Premium	Premium	Premium	-
2023-06-06	Premium	acquired	Premium	Premium	Premium	-

TNGX - Tango Therapeutics, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for TNGX